A real-world study to assess the disease control of moderate to severe atopic dermatitis in patients receiving dupilumab therapy, with atopic dermatitis control tool in Gulf countries.

Purpose/aim Of The Study: There is limited real-world evidence regarding the effectiveness and safety of dupilumab in Gulf countries. The study aimed to evaluate atopic dermatitis (AD) disease control in adult and adolescent patients (≥12 years) treated with dupilumab in Gulf countries.

Materials And Methods: This observational study included patients with moderate-to-severe AD who initiated dupilumab within 30 days.

'Monkeypox 2.0': Case series on a reconditioned virus causing sexually transmissible disease in urban population.

Background: MPOX (Monkeypox) viral infection, a zoonotic disease previously confined to the African sub-continent, has caught attention worldwide recently due to its resurgence in a new 'avatar' among urban communities. Dermatologists in the U. A.

Bullous Mastocytosis: A Rare Variant of Diffuse Cutaneous Mastocytosis.

Mastocytosis is a disease of the mast cells caused by an increase in the number of mast cells due to abnormal proliferation. The disease is associated with a mutation in the gene, which is a key factor in the development of mast cells. Mastocytosis is classified into two main groups, namely, cutaneous and systemic mastocytosis, based on the site of mast cell accumulation.

A Case of Bullous Pemphigoid in a Five-Month-Old Female: A Rare Presentation.

Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease, characterized by the presence of tense bullae and erosions of the skin and rarely at the mucous membranes. It often presents in the elderly population, but the incidence is rare in children and infants, with few reported cases in this population in the literature. We report a rare presentation of bullous pemphigoid in a five-month-old girl who presented to our clinic.

Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study.

Background: Sleep disturbance is a prominent symptom of atopic dermatitis (AD) and can result in insomnia, daytime fatigue, drowsiness, reduced productivity and impaired quality of life (QoL).

Objectives: The Dupilumab Effect on Sleep in AD Patients (DUPISTAD) phase IV randomized double-blinded placebo-controlled study evaluated the impact of dupilumab treatment on sleep and other patient- and physician-reported outcomes.

Methods: Adults with moderate-to-severe AD were randomized 2 : 1 to dupilumab 300 mg once every 2 weeks (q2w) or placebo for 12 weeks; concomitant topical corticosteroids were permitted.